A phase I/II study of continuous infusion suramin in patients with hormone refractory prostate cancer: Toxicity and response

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 1-8

  Bowden, Christopher J ^a,b   Figg, William D ^a   Dawson, Nancy A ^a,c   Sartor, Oliver ^a,d   Bitton, Roberto J ^a,e   Weinberger, Maribeth S ^a,d   Headlee, Donna ^a   Reed, Eddie ^a   Myers, Charles E ^a,b   Cooper, Michael R ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adaptive control with feedback; Concentration controlled trial; Flutamide; Flutamide withdrawal; Pharmacokinetics; Prostate cancer; Suramin; Toxicity

Indexed keywords

FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CATHETER INFECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; FATIGUE; HUMAN; INTRAVENOUS CATHETER; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PARALYSIS; PARESIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RASH; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUTAMIDE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURAMIN;

EID: 0029827498     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050531     Document Type: Article

References (25)

1. Bitton R, Figg WD, Venzon DJ, Dalakas M, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR (1995) Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 13:2223
2. Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, Klecker RW, Redfield RR, Mitsuya H, Hoth DF, Gelmann E, Groopman JE, Resnick L, Gallo RC, Myers CE, Fauci AS (1985) Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 2:627
3. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, Groopman JE, Gill PS, Volberding PA, Poiesz BJ, Gottlieb MS, Holden H, Volsky DJ, Silver SS, Hawkins MJ (1987) Suramin therapy in AIDS and related disorders. JAMA 258:1347
4. Cooper MR, Lieberman R, LaRocca RV, Gernt PR, Weinberger MS, Headlee DJ, Kohler DR, Goldspiel BR, Peck CC, Myers CE (1992) Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther 52:11
5. Dawson N, Cooper MR, Figg WD, Headlee D, Thibault A, Bergan R, Tompkins A, Steinberg S, Sausville E, Myers CE, Sartor O (1995) Activity of suramin in hormone refractory prostate cancer is diminished when hydrocortisone and flutamide withdrawal are removed as potentially confounding variables. Cancer 76:453
6. Eisenberger MA, Fontana JA (1992) Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer. J Natl Cancer Inst 84:3
7. Eisenberger MA, Reyno LM, Jodrell DI (1993) Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Clin Oncol 85:611
8. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski E, Lowitt MH, Jacobs SC, Egorin MJ (1993) Suramin, an active drug for prostate cancer: interim observation in a Phase I trial. J Natl Cancer Inst 85:611
9. Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE (1995) The effect of discontinuing flutamide in patients with hormone-refractory prostate cancer. Am J Med 98:412
10. Hosang M (1985) Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 29:265
11. Jodrell DI, Reyno LM, Sridhara R, Eisenberger MA, Tkaczuk KH, Zuhowski EG, Sinibaldi VJ, Novak MJ, Egorin MJ (1994) Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 12:166
12. LaRocca RV, Meer J, Gilliatt DM, Stein CA, Cassidy J, Myers CE, Dalakas MC (1990) Suramin-induced polyneuropathy. Neurology 40:954
13. LaRocca RV, Stein CA, Danesi R, Jamis-Dow CA, Weiss GH, Myers CE (1990) Suramin in adrenal cancer: modulation of steroid hormone production, cytoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 71:497
14. LaRocca RV, Cooper MR, Uhrich M, Danesi R, Walther MM, Linehan WM, Myers CE (1991) Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am 18:123
15. LaRocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM, Myers CE (1991) Effect of suramin on human prostate cancer cells in vitro. J Urol 145:393
16. LaRocca RV, Stein CA, Danesi R, Cooper MR, Uhrich M, Myers CE (1991) A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer 67:1509
17. LaRocca RV, Cooper MR, Stein CA, Kohler D, Uhrich M, Weinberger E, Myers CE (1992) A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. Ann Oncol 3:571
18. Levine AM, Gill PS, Cohen J, Hawkins JG, Formenti SC, Aguilar S, Meyers PR, Krailo M, Parker J, Rasheed S (1986) Suramin antiviral therapy in the acquired immunodeficiency syndrome. Ann Intern Med 105:32
19. Myers CE, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan WM (1992) Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881
20. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS (1991) The effect of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145:199
21. Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566
22. Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, Forrest A (1992) Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 52:64
23. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7:499
24. Supko JG, Malspeis L (1993) A rapid isocratic HPLC assay of suramin in human plasma. J Liq Chromatogr 13:727
25. Wittes RE (1991/1992) Appendix A: grading of toxicity. In: Wittes RE (ed) Manual of oncologic therapeutics. J.B. Lippincott Philadelphia, p 445